RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cartesian Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.08−0.19 (-3.03%)
Close on Oct 19, 2026
- Market cap
- $181.55M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
29.3%
9M of 30M shares
Institutional holders
96
25 new, 12 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
1 buys · 3 sales
Net sold $52.88K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Timothy A. Springer | 9,555,394 | 36.90% | 13D (active) amendment | Jan 13, 2025 |
| Murat Kalayoglu | 5,833,971 | 19.90% | 13D (active) amendment | Mar 31, 2026 |
| Squarepoint Capital LLP | 2,209,601 | 8.30% | 13G (passive) | Mar 9, 2026 |
| Barclays PLC | 1,760,326 | 5.99% | 13G (passive) | Jun 30, 2026 |
| Abigail P. Johnson | 1,366,989 | 5.30% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RNAC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Squarepoint Ops LLC | 2,254,619 | 7.45% | $23.49M | +16,133 | 0.03% |
| BlackRock, Inc. | 819,239 | 2.71% | $8.54M | +220,131 | 0.00% |
| 683 Capital Management, LLC | 650,000 | 2.15% | $6.77M | +320,000 | 0.33% |
| Vanguard Capital Management LLC | 555,823 | 1.84% | $5.79M | +148,226 | 0.00% |
| FMR LLC | 368,429 | 1.22% | $3.84M | −431,314 | 0.00% |
| Geode Capital Management, LLC | 356,525 | 1.18% | $3.72M | +92,831 | 0.00% |
| Aqr Capital Management LLC | 356,456 | 1.18% | $3.71M | +272,436 | 0.00% |
| Millennium Management LLC | 309,887 | 1.02% | $3.23M | +25,570 | 0.00% |
| Two Sigma Investments, LP | 296,293 | 0.98% | $3.09M | +128,980 | 0.00% |
| State Street Corp | 249,212 | 0.82% | $2.60M | +48,875 | 0.00% |
| Marshall Wace, Llp | 232,919 | 0.77% | $2.43M | −18,196 | 0.00% |
| UBS Group AG | 208,647 | 0.69% | $2.17M | +71,807 | 0.00% |
| Jupiter Topco LLC | 200,905 | 0.66% | $2.09M | New | 0.00% |
| Ironwood Investment Management LLC | 170,087 | 0.56% | $0 | – | 0.00% |
| Privium Fund Management B.V. | 151,675 | 0.50% | $1.58M | −27,439 | 0.29% |
| Northern Trust Corp | 105,698 | 0.35% | $1.10M | +13,706 | 0.00% |
| ADAR1 Capital Management, LLC | 98,877 | 0.33% | $1.03M | New | 0.05% |
| Vanguard Fiduciary Trust Co | 91,854 | 0.30% | $957.12K | +21,558 | 0.00% |
| Vanguard Portfolio Management LLC | 87,317 | 0.29% | $909.84K | +26,734 | 0.00% |
| Diadema Partners LP | 87,057 | 0.29% | $907.13K | New | 0.11% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 96 | 9M | 29.3% | 25 / 44 | 12 / 12 | 3M | 1M |
| Q1 2026 | 84 | 7M | 24.2% | 27 / 29 | 15 / 12 | 4M | 1M |
| Q4 2025 | 70 | 5M | 17.7% | 16 / 22 | 18 / 15 | 1M | 2M |
| Q3 2025 | 69 | 6M | 20.4% | 6 / 22 | 22 / 4 | 0M | 1M |
| Q2 2025 | 67 | 7M | 21.8% | 8 / 22 | 21 / 14 | 0M | 3M |
| Q1 2025 | 73 | 9M | 30.7% | 13 / 22 | 20 / 7 | 0M | 0M |
| Q4 2024 | 69 | 9M | 31.0% | 15 / 30 | 10 / 10 | 1M | 1M |
| Q3 2024 | 64 | 10M | 32.7% | 16 / 20 | 9 / 14 | 5M | 1M |
| Q2 2024 | 63 | 6M | 21.0% | 57 / 3 | 1 / 1 | 6M | 0M |
| Q1 2024 | 7 | 0M | 0.3% | 4 / 1 | 0 / 0 | 0M | 0M |
| Q4 2023 | 3 | 0M | 0.3% | 3 / 0 | 0 / 1 | 0M | 0M |
| Q3 2023 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RNAC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Select Biotechnology Portfolio | 5,385,728 | 17.80% | $1.56M | 0.03% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 1,117,119 | 3.69% | $323.96K | 0.00% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 555,522 | 1.84% | $161.10K | 0.00% | May 31, 2026 |
| Vanguard Explorer Fund | 528,838 | 1.75% | $95.19K | 0.00% | Jul 31, 2026 |
| Small Company Growth Portfolio | 414,811 | 1.37% | $74.67K | 0.00% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 376,309 | 1.24% | $3.92M | 0.00% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 366,554 | 1.21% | $2.76M | 0.05% | May 31, 2026 |
| iShares Russell 2000 ETF | 338,605 | 1.12% | $3.53M | 0.00% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 265,512 | 0.88% | $613.12K | 0.01% | Jul 31, 2026 |
| WisdomTree U.S. SmallCap Fund | 242,132 | 0.80% | $33.03K | 0.00% | Jun 30, 2026 |
| Janus Henderson Small Cap Growth Alpha ETF | 195,163 | 0.65% | $1.52M | 0.42% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 188,029 | 0.62% | $54.53K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 169,730 | 0.56% | $1.77M | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 145,588 | 0.48% | $42.22K | 0.00% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 144,043 | 0.48% | $1.12M | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Carsten Brunn | President and CEO, Director | 323,530 | 1.07% | Jan 8, 2026 |
| Milos Miljkovic | Chief Medical Officer | 58,820 | 0.19% | Jan 8, 2026 |
| Blaine Davis | Chief Financial Officer | 121,220 | 0.40% | Jan 8, 2026 |
| Emily English | Chief Operations Officer | 94,226 | 0.31% | Jan 6, 2026 |
| June Ann Seymour | Chief Accounting Officer | 6,500 | 0.02% | Jan 6, 2026 |
| Christopher M. Jewell | Chief Scientific Officer | 62,490 | 0.21% | Jan 13, 2025 |
| Metin Kurtoglu | Chief Technology Officer | 62,258 | 0.21% | Jan 7, 2025 |
| Michael Singer | Director | 544,381 | 1.80% | Mar 13, 2026 |
| Timothy C. Barabe | Director | 56,966 | 0.19% | Jan 6, 2026 |
| Patrick J. Zenner | Director | 12,974 | 0.04% | Jan 6, 2026 |
| Nishan M. DeSilva | Director | 11,366 | 0.04% | Jan 6, 2026 |
| Timothy A. Springer | Director, 10% owner | 9,633,493 | 31.84% | Jan 6, 2026 |
| Kemal Malik | Director | 11,133 | 0.04% | Jan 6, 2026 |
| Adrian Ion Bot | Director | 5,800 | 0.02% | Dec 18, 2025 |
| Carrie Smith Cox | Director | 15,629 | 0.05% | Jan 6, 2025 |
| Elizabeth Hoge | 10% owner | 5,820,260 | 19.24% | Apr 6, 2026 |
| One Eight Three Four Irrevocable Trust Seven | 10% owner | 5,061,637 | 16.73% | Apr 6, 2026 |
| Murat Kalayoglu | 10% owner | 5,820,260 | 19.24% | Apr 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Murat Kalayoglu 10% owner | Apr 2, 2026 | Option exercise | +758,001 | – | – | 5,313,261 |
| Elizabeth Hoge 10% owner | Apr 2, 2026 | Option exercise | +758,001 | – | – | 5,313,261 |
| Michael Singer Director | Mar 13, 2026 | Gift | −6,555 | – | – | 49,578 |
| Carsten Brunn President and CEO, Director | Jan 6, 2026 | Sale | −23,766 | $6.82 | $162.08K | 323,530 |
| Milos Miljkovic Chief Medical Officer | Jan 6, 2026 | Sale | −3,573 | $6.82 | $24.37K | 58,820 |
| Blaine Davis Chief Financial Officer | Jan 6, 2026 | Sale | −10,591 | $6.82 | $72.23K | 121,220 |
| June Ann Seymour Chief Accounting Officer | Jan 2, 2026 | Award | +6,500 | – | – | 6,500 |
| Murat Kalayoglu Director, 10% owner | Jan 2, 2026 | Award | +2,600 | – | – | 511,577 |
| Carsten Brunn President and CEO, Director | Jan 2, 2026 | Award | +143,200 | – | – | 347,296 |
| Kemal Malik Director | Jan 2, 2026 | Award | +2,600 | – | – | 11,133 |
| Nishan M. DeSilva Director | Jan 2, 2026 | Award | +2,600 | – | – | 11,366 |
| Timothy A. Springer Director, 10% owner | Jan 2, 2026 | Award | +2,600 | – | – | 8,646,285 |
| Blaine Davis Chief Financial Officer | Jan 2, 2026 | Award | +37,000 | – | – | 131,811 |
| Timothy C. Barabe Director | Jan 2, 2026 | Award | +2,600 | – | – | 56,966 |
| Emily English Chief Operations Officer | Jan 2, 2026 | Award | +24,000 | – | – | 94,226 |
| Milos Miljkovic Chief Medical Officer | Jan 2, 2026 | Award | +27,000 | – | – | 62,393 |
| Patrick J. Zenner Director | Jan 2, 2026 | Award | +2,600 | – | – | 12,974 |
| Michael Singer Director | Jan 2, 2026 | Award | +2,600 | – | – | 56,133 |
| Emily English Chief Operations Officer | Dec 30, 2025 | Option exercise | +7,500 | $3.30 | $24.75K | 70,226 |
| Adrian Ion Bot Director | Dec 16, 2025 | Award | +5,800 | – | – | 5,800 |
| Timothy C. Barabe Director | Dec 4, 2025 | Buy | +30,000 | $6.86 | $205.80K | 54,366 |
| Emily English Chief Operations Officer | Nov 28, 2025 | Option exercise | +7,500 | $3.30 | $24.75K | 62,726 |
| Michael Singer Director | Nov 18, 2025 | Gift | −20,000 | – | – | 53,533 |
| Emily English Chief Operations Officer | May 12, 2025 | Option exercise | +7,500 | $3.30 | $24.75K | 55,226 |
| Emily English Chief Operations Officer | Apr 15, 2025 | Option exercise | +7,500 | $3.30 | $24.75K | 47,726 |
| Timothy A. Springer Director, 10% owner | Apr 11, 2025 | Buy | +36,338 | $10.77 | $391.36K | 656,513 |
| Timothy A. Springer Director, 10% owner | Apr 11, 2025 | Buy | +6,412 | $10.77 | $69.06K | 8,643,685 |
| Timothy A. Springer Director, 10% owner | Apr 10, 2025 | Buy | +3,451 | $10.92 | $37.68K | 620,175 |
| Timothy A. Springer Director, 10% owner | Apr 10, 2025 | Buy | +609 | $10.92 | $6.65K | 8,637,273 |
| Timothy A. Springer Director, 10% owner | Apr 10, 2025 | Buy | +7,966 | $10.43 | $83.09K | 8,636,664 |
| Timothy A. Springer Director, 10% owner | Apr 10, 2025 | Buy | +45,144 | $10.43 | $470.85K | 616,724 |
| Timothy A. Springer Director, 10% owner | Apr 9, 2025 | Buy | +7,342 | $9.43 | $69.24K | 8,628,667 |
| Timothy A. Springer Director, 10% owner | Apr 9, 2025 | Buy | +41,604 | $9.43 | $392.33K | 571,402 |
| Timothy A. Springer Director, 10% owner | Apr 9, 2025 | Buy | +178 | $9.95 | $1.77K | 571,580 |
| Timothy A. Springer Director, 10% owner | Apr 9, 2025 | Buy | +31 | $9.95 | $308 | 8,628,698 |
| Timothy A. Springer Director, 10% owner | Mar 20, 2025 | Buy | +54,889 | $15.59 | $855.72K | 8,621,325 |
| Timothy A. Springer Director, 10% owner | Mar 19, 2025 | Buy | +20,234 | $14.97 | $302.90K | 8,566,436 |
| Timothy A. Springer Director, 10% owner | Mar 18, 2025 | Buy | +14,740 | $14.42 | $212.55K | 8,546,202 |
| Timothy A. Springer Director, 10% owner | Jan 14, 2025 | Buy | +4,022 | $18.00 | $72.40K | 8,531,462 |
| Timothy A. Springer Director, 10% owner | Jan 13, 2025 | Buy | +8,983 | $17.78 | $159.72K | 8,527,440 |
| Timothy A. Springer Director, 10% owner | Jan 13, 2025 | Buy | +7,962 | $16.86 | $134.24K | 8,518,457 |
| Christopher M. Jewell Chief Scientific Officer | Jan 10, 2025 | Option exercise | +9,000 | $3.23 | $29.07K | 62,490 |
| Metin Kurtoglu Chief Technology Officer | Jan 6, 2025 | Sale | −2,458 | $16.83 | $41.37K | 62,258 |
| Emily English Chief Operations Officer | Jan 6, 2025 | Sale | −906 | $16.83 | $15.25K | 40,226 |
| Milos Miljkovic Chief Medical Officer | Jan 6, 2025 | Sale | −948 | $16.83 | $15.95K | 35,393 |
| Blaine Davis Chief Financial Officer | Jan 6, 2025 | Sale | −4,028 | $16.83 | $67.79K | 94,811 |
| Christopher M. Jewell Chief Scientific Officer | Jan 6, 2025 | Sale | −1,286 | $16.83 | $21.64K | 53,490 |
| Carsten Brunn President and CEO, Director | Jan 6, 2025 | Sale | −8,708 | $16.83 | $146.56K | 204,096 |
| Metin Kurtoglu Chief Technology Officer | Jan 3, 2025 | Sale | −2,417 | $16.72 | $40.41K | 64,716 |
| Emily English Chief Operations Officer | Jan 3, 2025 | Sale | −891 | $16.72 | $14.90K | 41,132 |
| Milos Miljkovic Chief Medical Officer | Jan 3, 2025 | Sale | −932 | $16.72 | $15.58K | 36,341 |
| Blaine Davis Chief Financial Officer | Jan 3, 2025 | Sale | −3,961 | $16.72 | $66.23K | 98,839 |
| Christopher M. Jewell Chief Scientific Officer | Jan 3, 2025 | Sale | −1,264 | $16.72 | $21.13K | 54,776 |
| Carsten Brunn President and CEO, Director | Jan 3, 2025 | Sale | −8,563 | $16.72 | $143.17K | 212,804 |
| Christopher M. Jewell Chief Scientific Officer | Jan 2, 2025 | Award | +16,100 | – | – | 56,040 |
| Murat Kalayoglu Director, 10% owner | Jan 2, 2025 | Award | +2,600 | – | – | 508,977 |
| Carsten Brunn President and CEO, Director | Jan 2, 2025 | Award | +57,500 | – | – | 221,367 |
| Carrie Smith Cox Director | Jan 2, 2025 | Award | +2,600 | – | – | 15,629 |
| Milos Miljkovic Chief Medical Officer | Jan 2, 2025 | Award | +19,000 | – | – | 37,273 |
| Metin Kurtoglu Chief Technology Officer | Jan 2, 2025 | Award | +16,100 | – | – | 67,133 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Miljkovic Milos Former Affiliate | Jun 9, 2026 | 35,038 | $232.73K | Jun 9, 2026 | Exercise of Options Under a Registered Plan |
| Miljkovic Milos Former Affiliate | Jun 2, 2026 | 3,924 | $25.15K | Jun 2, 2026 | Restricted stock vesting under a registered plan |
| M. Jewell Christopher Former Affiliate | Jan 13, 2026 | 9,000 | $68.94K | Jan 13, 2026 | Exercise of options under a registered plan |
| M. Jewell Christopher Former Affiliate | Jan 9, 2026 | 1,510 | $12.11K | Jan 9, 2026 | Restricted stock vesting under a registered plan |
| M. Jewell Christopher Former Affiliate | Nov 19, 2025 | 26,935 | $192.59K | Nov 19, 2025 | Previously Exercised Options |
| Kurtoglu Metin Officer | Dec 10, 2024 | 2,901 | $70.64K | Dec 10, 2024 | Exercise of options under a registered plan |
| Kurtoglu Metin Officer | Dec 9, 2024 | 10,763 | $274.49K | Dec 9, 2024 | Exercise of options under a registered plan |
| Kurtoglu Metin Officer | Nov 21, 2024 | 32,789 | $546.56K | Nov 21, 2024 | Exercise of options under a registered plan |
| Kurtoglu Metin Officer | Nov 20, 2024 | 5,700 | $98.57K | Nov 20, 2024 | Exercise of options under a registered plan |
| Kurtoglu Metin Officer | Nov 19, 2024 | 200 | $3.90K | Nov 19, 2024 | Exercise of options under a registered plan |
| Kurtoglu Metin Officer | Nov 18, 2024 | 34,400 | $632.64K | Nov 18, 2024 | Exercise of options under a registered plan |
| M. Jewell Christopher Officer | Nov 15, 2024 | 16,065 | $274.09K | Nov 15, 2024 | Exercise of options under a registered plan |
| Miljkovic Milos Officer | Nov 15, 2024 | 20,000 | $342.89K | Nov 15, 2024 | Exercise of options under a registered plan |
| Kurtoglu Metin Officer | Nov 15, 2024 | 22,068 | $379.50K | Nov 15, 2024 | Exercise of options under a registered plan |
| M. Jewell Christopher Officer | Nov 14, 2024 | 36,050 | $600.95K | Nov 14, 2024 | Exercise of options under a registered plan |